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Conscious sedation versus monitored 
anaesthesia care 
To the Editor: I share the concerns of Stefanutto and Ruttmann1 
regarding the safety of sedation practice done by untrained 
sedation practitioners. Non-anaesthesiologists are involved in 
sedation worldwide, and I agree that sedation of patients for 
minor procedures ‘is here to stay’. But I am concerned that a 
dark picture is painted of conscious sedation, which is very safe 
when done by trained practitioners.
In order to help solve the problem, we need to know who 
the authors are referring to when they state that ‘Currently 
sedation is a poorly controlled practice, often performed in 
potentially unsafe environments by unqualified personnel who 
may be unable to deal with complications’. The authors claim 
that it is ‘common practice with sedation [for] the sedative 
drugs [to be] given in large doses to attempt to achieve a calm, 
pain-free patient’ – and refer to a 1972 article! There are many 
publications on conscious sedation and we all know and teach 
that titration is required to reach an optimal level of sedation 
and to avoid complications. 
The authors’ comments on ‘Where does this leave us in South 
Africa?’ leave readers, not all of whom are anaesthesiologists, 
uninformed about what is being done in this country. The South 
African Dental Association published guidelines2 on conscious 
sedation to address uncontrolled practice by ‘unqualified 
practitioners’. The South African Society of Anaesthetists has 
also published guidelines. In a document on safe sedation the 
UK Academy of Medical Royal Colleges and their Faculties, 
chaired by the Royal College of Anaesthetists, stated, ‘the key 
point is that safety will be optimized only if practitioners use 
defined methods of sedation for which they have received 
formal training’. The universities of Stellenbosch and the 
Western Cape have a university-accredited course on sedation 
and pain control/conscious sedation. It is presented by 
anaesthesiologists and attended by national and international 
students. We write a monthly article for the Journal of the Dental 
Association of South Africa covering all aspects of safe sedation 
practice. We also present a postgraduate university-accredited 
certificate course on sedation and pain management in 
association with University College London and are developing 
conscious sedation programmes. Our symposium in London in 
November 2006 was accredited for CPD by the Royal College of 
Anaesthetists.
The authors state that the term ‘conscious sedation’ has 
been ‘expanded, twisted and manipulated’. This is true – it is 
a worldwide phenomenon that practitioners do not always 
do what they are told. A recent survey showed that 70% of 
sedation practitioners follow guidelines, 20% follow them more 
or less, and 10% not at all (personal communication).
The authors claim that there are no ‘absolute figures of 
complications related to sedation available in South Africa’. 
How then can they say that it is poorly controlled? For 15 years 
we have run daily sedation clinics at the Tygerberg campus 
with no mortality, and no major complications in adults or 
children. Their statement, ‘based on the few studies on the 
subject ... the majority of deaths occur’ creates the impression 
that there are many deaths related to conscious sedation, 
which is not the case (one of the two studies they refer to was 
published in 1988!). Are they talking about conscious or deep 
sedation?  In a study on the safety of conscious sedation3 no 
complications were reported for 99.1% of those receiving 
conscious sedation, and 98.5% of those receiving deep 
sedation/general anaesthesia. This and other studies clearly 
demonstrate positive outcomes if sedation practitioners are 
trained.  
General anaesthesia should not be compared with conscious 
sedation as there is a place for both in patient care.  Sedation 
is not perceived as a ‘cheap option’ by anaethesiologists. We 
value the safety and comfort of our patients highly. Operation 
waiting lists for our patients from the community have been cut 
substantially, which is a positive factor for patients. 
Leaders who influence policies in their field of practice may 
have strong prejudices and pride in past achievements. It is 
time we looked beyond our personal status and support the 
wide variety of practitioners practising sedation.
James Roelofse
Professor and Head of Sedation and Pain Control
University of the Western Cape
jaroelofse@uwc.ac.za
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Drs Stefanutto and Ruttmann reply: Our article seems to have 
been misread by Professor Roelofse, who projects a sense of 
feeling ‘under attack’. If that is the case, we must apologise. 
However, we must also point out that as an established 
university-based sedation centre, the author’s unit was most 
certainly not in any way the forum at which the article was 
aimed.
What does arise from the letter though, is that there is no 
clarity on ‘what is right and what is wrong’ when it comes to 
the practice of sedation in South Africa. Furthermore, as we also 
said in our article, there are guidelines available through SASA 
– however, sedation is usually not practised by anaesthetists. 
Roelofse makes it look as though a rate of 98.5% with no 
complications is laudable. However, this figure means that 15 
people out of every 1 000 receiving ‘deeper sedation’ would 
have complications. Presumably this could easily equate to 15 
people per day in a population of around 40 million? And that 
is 15 people receiving a ‘safe’ procedure expected to have no 
complications!
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An important issue to address is the difference between 
‘sedation’ and the drift into anaesthesia that has been defined 
as ‘MAC’ (monitored anaesthesia care) in the literature. 
There is no doubt that a well-trained and experienced health 
care provider has the ability to give incremental doses of the 
appropriate drugs to maintain the patient in a relaxed, sedated 
state, while ensuring that s/he is still fully responsive and not 
drifting into a non-responsive, deeper state. The question is: Do 
we in South Africa identify, maintain and monitor this state and 
therefore prevent the drift into deeper sedation? 
We are afraid that Roelofse’s letter, which may well be 
interpreted by some as a ‘shotgun approach’ to our article, is 
perhaps not what we need in this country when it comes to the 
practice of sedation. What is clear from both the article and the 
letter is that while sedation is here to stay, there are still no clear, 
basic guidelines for this practice that are understood, accepted 
and practised across the medical disciplines in South Africa. 
We therefore challenge Roelofse, and anyone who has an 
interest in this, to contact us so that together we can formulate 
appropriate practice guidelines for South Africa which can 
be unanimously adopted and adhered to by all medical 
practitioners administering sedation.
To the Editor: As a practising sedationist I share the concerns 
raised by Stefanutto and Ruttmann in a recent issue of the 
Journal.1 A sedationist should be an experienced anaesthetist 
who has training in conscious sedation. Anaesthetic experience 
does not necessarily mean that one is able to practise conscious 
sedation, especially in the out-of-theatre environment. That is 
where GANA (general anaesthesia no airway) or ‘anaesthesia 
lite’ originates.
Conscious sedation should only be practised in a safe 
environment. Monitoring and resuscitation equipment should 
therefore be on a par with that found in an operating theatre. 
Patient safety may not be compromised. Here patient selection 
and the type of procedure performed are also of the utmost 
importance.
To ensure that safety standards are met the sedationist must 
be trained. The surgeon or dentist must be informed regarding 
conscious sedation, as they are also responsible for the safety 
of their patients. It would be a great advantage if patients also 
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Utilisation of pathology procedures
To the Editor: The article on utilisation of pathology procedures 
in the South African private pathology sector, published in 
the SAMJ recently,1 refers. Solutions are proposed that have 
no bearing on the ‘factual’ material presented, and apersions 
are cast designed to advance the aspirations of Veripath, a 
commercial managed care enterprise. The conclusions have 
long been the credo of Veripath and are not based on the claims 
database surveyed. Veripath input is acknowledged, but the 
author should indicate that he is a full-time employee of the 
managed care company. [Dr Pretorius declared his relationship 
with Veripath and the medical aid industry in a letter accompanying 
the original submission of his article. – Editor]
Bias and vested interest flaws any useful examination of the 
material by the author or his cohorts. Although the information 
bears examination, any extrapolation is flawed because the 
baselines are neither decided nor constant. The SAMJ has 
been used as a platform to advance not scientific conclusions, 
but a thinly veiled sales pitch that is being touted to advance 
their credibility. The CPD questionnaire seems to indicate that 
the article has been accepted as the final word on the topic. It 
cannot be. There is no dearth of published articles on laboratory 
utilisation, but when new pathology tests seem to arrive almost 
every day, articles published up to 33 years ago might not be 
entirely relevant except to advance vested interests!
With the advent of ICD-10 much more scientific and locally 
relevant information related to clinical diagnosis, treatment and 
outcome will be available, and not postulates that the author 
questions, but advances as evidence to support the views of 
Veripath. The latter, like other managed care organisations, 
extracts its bit of the health care rand. Veripath does not have 
custodianship of the information, and is not credibly qualified 
to advance opinions on its clinical application. 
It is time to cut out the middlemen, who are not needed by 
funders or pathologists, between whom a working relationship 
is possible, as with all professional groups. Pathologists, who 
it seems are deemed the villains of medicine, will welcome the 
constructive evaluation of laboratory medicine, which will be 
possible when ICD-10 data become available. Funders must 
share and use this information constructively rather than adopt 
an adversarial approach to problem solving. Pathology is a 
referral discipline and the referring doctor largely drives the 
mode of testing. Pathologists are an integral and indispensable 
part of the health care system, adding significant value to the 
health care outcome. 
The reasons for medical analysis, including pathology, are 
investigative to ascertain abnormality, quantitative to quantify 
or stage disease, confirmatory or defensive to confirm disease, 
and to ensure that litigious liability has not been overlooked. 
It invites assumption of legal liability should prescription be 
imposed. Castigating pathologists for using their expertise 
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to further investigate abnormal findings is tantamount to 
prescribing to a physician or surgeon that patient care should 
be related solely to the reason for referral, and that even if 
additional findings are made, no further investigation or care 
should be advanced until permission has been obtained. 
As with all involved in patient care, pathologists must 
order further tests based on the outcome of prior testing. This 
is sometimes life saving. Their expertise is based on general 
medical training, specialist training in laboratory medicine, 
and clinicopathological correlation. To suggest otherwise is to 
relegate pathologists to the level of technicians who merely 
provide results at the behest of the referring doctor without 
interpretation.
With tongue in cheek, would one solution not be to ban 
pathology testing altogether? But that would not be to the 
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To the Editor: An editorial1 referring to an article in the same 
issue of the Journal2 suggests that more appropriate use of 
pathology investigations can save up to R115 million. Pretorius2 
states that a cost saving of 15% is potentially achievable if the 
lowest-cost laboratory is accepted as ideal behaviour, but ‘It 
is debatable whether the lowest utilisation in this sample represents 
ideal or acceptable test utilisation’ (my emphasis). Neither author 
justifies or analyses the proposed saving based on patient 
outcomes or disease profiles. Their apparent objective is to 
demonstrate laboratory overuse. The debate should be about 
the value and applicability of pathology in patient care. No 
responsible pathologist supports over-investigation of patients, 
but neither should under-investigation be sanctioned. 
Raath presented data from an industry-wide modelling tool 
of the annual statutory returns of all registered schemes and 
options for the period 2002 onwards at the BHF conference 
in Durban in July 2006, and concluded that the weighted 
percentage increase in benefits to pathology was a fraction of 
1%. His figures contrast sharply with those of Pretorius.2 The 
2.3 billion expenditure on pathology in South Africa constitutes 
4.5% of total contributions to medical schemes. Non-health 
care expenditure absorbs 15% of total contributions. In 2005 
non-health care expenditure rose by approximately 9.6% to 
R7.8 billion, with the major components being administration 
R5.4 billion (annual increase of 10.5%), managed care fees R1.3 
billion, and broker fees R0.8 billion (annual increase of 21.1%). 
From 2000 to 2005 non-health care expenditure increased by 
89.5%.3 Managed care expenditure therefore amounts to about 
50% of expenditure on pathology.
Pathology is a referral specialty. Pathologists are medical 
specialists and are the bridge between the clinician and the 
laboratory. The Royal College of Pathologists advocates: 
‘Other relevant tests may be added to, or substituted for, those 
originally requested.’3
Members of the National Pathology Group (NPG) of SAMA 
must adhere to specific protocols for laboratory request forms 
– only academically defensible test profiles may appear, it must 
be possible to request any test individually, and the content of 
profiles must be listed on the laboratory request pad.  Clinicians 
are at liberty to request any test individually, or a combination 
of tests. 
Veripath, the managed care company that employs Pretorius, 
is campaigning to replace current laboratory request forms 
with blank paper on which tests must be handwritten. This 
will dramatically increase the error rate. The transcription 
error rate from incorrectly handwritten laboratory request 
forms in Australia has been estimated to reach 17%.4 In fact, 
online test ordering with data transmission to the laboratory is 
increasingly the norm. 
Is rationing the sole objective? Pathologists contribute 
significantly to appropriate and cost-effective laboratory testing 
by publishing investigative guidelines and protocols.5 Much 
is made of the fact that the majority of the tests are common, 
of low complexity, and performed in bulk. The fee for a given 
test does not vary even if it is done as a single investigation 
during the day, after hours, or in the most remote laboratory. 
The cross-subsidisation of these services and tests ensures that 
a comprehensive laboratory service is broadly available to all 
patients.
The Australian system is essentially a national health 
system, with the state as guarantor of payment. The selective 
choice of certain components will not lead to a sustainable 
pathology service for South Africa. The Australian Association 
of Pathology Practices noted some of the other negative effects 
of the memorandum of understanding between pathologists 
and the Australian Government, including reforms being 
funding-based rather than aimed at best medical practice, 
discouragement of entrepreneurship due to limits to return on 
investment, and likelihood of unsustainability in the long run.6
The NPG is currently in the process of tariff revision.  In an 
extensive preliminary submission to the Council for Medical 
Schemes in 2006, 17.4 million billing line items were evaluated. 
This indicated a financial return of approximately 10% for 
pathology, provided that an increase of 7.5% was to be allocated 
to the National Health Reference Price List (NHRPL) for 2007. 
From this report it is obvious that the income for all services by 
laboratories is not excessive.
The NPG’s role is to ensure that pathology continues to fulfil 
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its vital role as the hidden science that saves lives and is not 
relegated to a ‘cost centre’!
Tjaart Erasmus
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Dr Pretorius replies: Attacking the messenger to obfuscate the 
message is Dr Harrison’s prerogative. He dismisses my article 
outright without providing a measured argument or alternative 
explanations on any of the findings. In the Council for Medical 
Schemes (CMS) annual report for 2005/6,1 the total benefit paid 
by medical schemes for pathology tests in 2005 increased by 
26.6% over 2004 (p. 88). The beneficiaries of all medical schemes 
increased by 2.6% (p. 47), and the NHRPL tariff increase was 
5.2% for 2005. The difference of 18.8% can only represent an 
increase in utilisation. My article under discussion reported 
a 14.5% increase in the cost per beneficiary who underwent 
pathology testing. If anything, the CMS report would suggest 
that the magnitude of the problem may be even greater than 
reported in the article.
To satisfy Harrison’s quest for recent literature I wish to refer 
him to an article in Clinical Chemistry2 that expresses similar 
concerns regarding test utilisation and in which the authors 
describe an innovative mechanism to manage utilisation at the 
test initiation stage.
Harrison states that pathology is a ‘referral discipline’, 
with testing driven by the referral doctor. He then contradicts 
himself by pontificating on the reasons why pathologists should 
be allowed to initiate additional testing without deference to the 
referring doctor or patient. What was discussed in the article 
was the phenomenon of reflex testing (a test triggered by the 
result of another test without pathologist intervention) and not 
additional tests as a result of clinical interaction. Although not 
relevant to the article, my personal opinion is that pathologists 
should play an active role in providing health care; this role 
extends to not doing tests that are ordered inappropriately, 
and initiating tests that are appropriate but not requested. 
What I cannot accept is the notion that as a ‘referral discipline’ 
pathologists should do inappropriate tests just because they are 
instructed to do so by referring doctors, and then in the same 
breath add tests on the basis that they have a responsibility for 
patient care.
It is unfortunate that Dr Harrison chose not to contribute to 
a discussion on the reason/s for the greater-than-anticipated 
increases in pathology expenditure.
I wish to thank Dr Erasmus for his comments. I am pleased 
that he agrees with me that both under- and over-investigation 
of patients should be frowned upon. Taking the cost per active 
beneficiary of the lowest cost provider and multiplying this 
amount with the total number of active beneficiaries from all 
providers in the sample was used to arrive at the quoted figure 
of a potential 15% saving in expenditure. This theoretical cost 
was then compared with the actual cost to estimate the quan-
tum of the potential saving. The statement that Erasmus has 
correctly quoted verbatim, qualified this potential saving.
The purpose of the comments on non-health care expenditure 
as well as the comments on the costing exercise of the NPG is 
not relevant to the discussion, and it escapes me why this was 
raised.  
Dr Erasmus misrepresents my efforts to address issues sur-
rounding the design of pathology request notes. The requi-
sitioning of laboratory tests (handwritten or electronic) has 
been shown in a number of articles to be a crucial interface in 
promoting appropriate utilisation of resources. I unashamedly 
advocate unambiguous requesting of individual tests by a 
competent clinician and fail to see how this can be interpreted 
as rationing.
In defence of maintaining the current version of the tick box 
request form, Erasmus quotes an error rate of 17%3 from an 
Australian article. This ‘evidence’ is then used to prove the 
unworkability of a proposed solution that was modelled on 
the Australian rules on laboratory request forms. Dr Erasmus 
is selectively quoting the worst performance achieved in the 
study. The median error rates, of various categories of errors 
examined, were in fact between 1.0 and 2.5%. This figure differs 
markedly from the 17% we are led to believe would be the 
result of implementing the recommendations in the article. 
Nowhere in the article by Khoury or in an accompanying 
editorial4 were handwritten request forms blamed for errors, 
nor was it suggested by any of the authors that the rules 
pertaining to the requisitioning of pathology tests in Australia 
be changed. Dr Erasmus’s concerns about the consequences of 
increased errors can therefore be dismissed.    
Lastly, Dr Erasmus is invited to submit for public scrutiny the 
academic evidence underlying the composition of the NPG-
sanctioned profiles.
1. Council for Medical Schemes Annual Report 2005/6. http://www.medicalschemes.com/
publications/ZipPublications/Annual%20Reports/CMS_annual_report_2005-6.pdf (accessed 
February 2007).
2. Poley MJ, Edelendos KI, Mosseveld M, et al. Cost consequences of implementing an 
electronic decision support system for ordering laboratory test in primary care: Evidence 
from a controlled prospective study in the Netherlands. Clin Chem 2007; 53: 213-219.
3. Khoury M, Burnett, Mackay MA. Error rates in Australian chemical pathology laboratories. 
Med J Aust 1996; 165: 128-130.
4. Bryant SJ. Ensuring quality in all phases of the pathology cycle. Med J Aust 1996; 165: 125-
126.
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Medicines Control Council and 
registration backlog of antiretrovirals 
To the Editor: Antiretroviral (ARV) medication must be taken 
faithfully in order to keep HIV in check. Some current regimens 
of highly active antiretroviral treatment (HAART) require 
taking many different pills, several times a day. Once-daily 
ARV formulations simplify dosing and could lead to better 
compliance. 
On 12 July 2006 Bristol-Myers Squibb and Gilead Sciences 
announced that the US Food and Drug Administration (FDA) 
had cleared Atripla, their fixed-dose combination tablet 
containing Stocrin/Sustiva (efavirenz) and Truvada (tenofovir 
and emtricitabine). Atripla is the second once-daily HAART 
regimen taken as a single pill to be approved by the FDA. 
Of the three ARVs in Atripla, only efavirenz is currently 
available in South Africa. The first fixed-dose combination of 
ARV medications to be approved by the FDA in January 2005 
was Aspen Pharmacare’s generic combination of lamivudine, 
zidovudine and nevirapine. It is a highly effective and widely 
used 3-in-1 combination, but unfortunately not available in 
South Africa as Aspen appears not yet to have applied for its 
registration with the Medicines Control Council (MCC).
When Aspen was asked in September 2006 whether it has 
applied to the MCC for registration of the generic combination 
of lamivudine, zidovudine and nevirapine, Gavin Wiggill, 
Product Manager for Aspen, provided an evasive equivocal 
statement from which it was unclear whether they had applied. 
If not, it is imperative that they do so immediately.
Research indicates that stavudine, used as part of the 
standard first-line regimen in the Department of Health’s HIV 
treatment guidelines, should be replaced by tenofovir, which 
is a potent, safe and well-tolerated ARV. Stavudine-related 
toxicity is one of the main reasons for discontinuation and/or 
changing the first-line regimen.
Few people on ARV treatment are accessing tenofovir in 
terms of the Medicines and Related Substances Act, as it is a 
time-consuming and onerous process to initiate that has to be 
reviewed every 6 months. Tenofovir is therefore effectively not 
available for treatment in public health clinics.
Both Gilead and Aspen pharmaceutical companies have 
applied for registration of tenofovir over the past few years 
but the MCC has yet to approve its registration, in spite of 
Aspen requesting fast-track review status for its registration 
in November 2005. On 24 September 2006 Aspen supplied 
additional information on tenofovir requested by the MCC, 
which has since indicated that tenofovir may possibly be 
registered by early 2007.
In a recent issue of the Sunday Times1 Mandisa Hela, the MCC 
registrar, admitted that there is a drug registration backlog, 
with an average registration time of between 2 and 3 years for 
new drugs (including ARVs) entering the South African market. 
Experts working for the MCC indicate that this is largely owing 
to the exodus of skilled staff and increasing numbers of new 
drug applications. Reviews and evaluations of new drugs for 
registration are mostly outsourced to busy academics. The MCC 
therefore appears to be badly resourced and unable to cope 
with its mandate. Hela claimed that applications for registration 
of ARVs were automatically fast-tracked, but declined to 
comment on the pending tenofovir application saying ‘that is 
confidential information’.  
The MCC should review new drugs that are fast-tracked 
by first checking if the FDA and European Union (EU) have 
approved them. If so, the MCC should only check if there are 
any issues specific to South Africa that merit concern and then 
immediately register them. Atripla was approved in less than 3 
months in the USA under the FDA’s fast-track programme, and 
was made available within days following its approval. In spite 
of this good news about the availability of Atripla in the USA, it 
may take a long time before it becomes available in South Africa 
given the tardiness of the MCC in registering new medications, 
including ARVs. 
Given the extent of the HIV/AIDS pandemic in South Africa, 
it is essential that the MCC facilitate the registration of these 
life-extending medications as rapidly as possible. The MCC 
should encourage pharmaceutical companies to apply for the 
registration of new ARVs as soon as they become available and 
ensure that the fast-track registration process is significantly 
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